Akebia Therapeutics price to free cash flow AKBA

Market value divided by free cash flow over the last twelve months, since 2017.

Today, Oct 23, 2026: 3.9×
10-year median: 10.1×
Against its 10-year history: 0th; percentile: 0 is its lowest day, 100 its highest
10-year range: 3.9× to 22.7×
Peer median: 11.4×

Akebia Therapeutics' price to free cash flow is 3.9× as of Oct 23, 2026.

That is below its ten-year median of 10.1×, lower than on 100% of days in the last ten years.

Over that time it ranged from 3.9× in Oct 2026 to 22.7× in Jun 2017.

The median for 10 large drugmakers of a similar size is 11.4×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	3.9×	3.9×	12.8×
2025	13.7×	12.7×	13.8×
2024	n/m a value too high to mean anything
2023	n/m a value too high to mean anything
2022	n/m a value too high to mean anything
2021	n/m a value too high to mean anything
2020	n/m a value too high to mean anything
2019	n/m a value too high to mean anything
2018	12.2×	12.2×	13.6×
2017	12.9×	6.4×	22.7×

Against its peers

Companies in Drug Manufacturers - General nearest Akebia Therapeutics' size, closest first, today.

Company	Price to free cash flow
AKBAAkebia Therapeutics	3.9×
NATRNatures Sunshine Products	11.8×
LFVNLifevantage	11.0×
SPROSpero Therapeutics	n/m
ARVNArvinas	n/m
ATNMActinium Pharmaceuticals	n/m
PBYIPuma Biotechnology	13.8×
IRWDIronwood Pharmaceuticals	n/m
ZVRAZevra Therapeutics	17.9×
CRMDCorMedix	2.4×
COLLCollegium Pharmaceutical	2.3×
Peer median	11.4×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Akebia Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.